Skip to main content
Publications
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Davis KL, Ubieto A, Nagar S, Zhang AJ, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A retrospective cohort study of treatment outcomes of adult patients with relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 Jun;62(6):1325-34. doi: 10.1080/10428194.2021.1919662
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y, Kajinami K. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018 Mar 23;82(4):1008-16. doi: 10.1253/circj.CJ-17-0811
Ajmera MR, Davis KL, Price G, Li L, Huang YJ, Price GL, Goyal RK, John WJ, Cuyun Carter G, Kaye JA, Boye ME. Economic outcomes associated with tumor histology among elderly patients with metastatic non–small cell lung cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A165.